The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
AACR 2021 | Changes in mast cell number & immunophenotype in patients with mastocytosis treated with avapritinib
Tracy George, MD, The University of Utah, Salt Lake City, UT, discusses the impact of avapritinib therapy for patients with indolent systemic mastocytosis on mast cell numbers and phenotype. Systemic mastocytosis is a rare disease, and in patients with advanced indolent disease, avapritinib, a selective tyrosine kinase inhibitor of activated KIT and PDGFRA, has demonstrated efficacy as evaluated in the PIONEER study (NCT03731260). Avapritinib resulted in a vast reduction in the number of mast cells in patients with indolent systemic mastocytosis and also altered the immunophenotype of aberrant cells. This interview took place at the virtual American Association for Cancer Research (AACR) Annual Meeting 2021.
Disclosures
Tracy George, MD, has served as a consultant for Blueprint Medicines Corporation.
